{{Drugbox
| IUPAC_name = (4''S'',7''S'',10''S'',13''S'',16''R'')-''N''-[(2''S'')-5-Amino-1-hydroxy-2-pentanyl]-7-(2-amino-2-oxoethyl)-10-[(2''R'')-2-butanyl]-13-''sec''-butyl-16-(1''H''-indol-3-ylmethyl)-''N''-methyl-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
| image = Barusiban.svg
| width = 250
| CAS_number = 285571-64-4
| ATC_prefix = None
| ATC_suffix =
| PubChem = 9832431
| DrugBank =
| ChemSpiderID = 8008159
| chemical_formula =
| C=40 | H=63 | N=9 | O=8 | S=1
| molecular_weight = 830.049 g/mol
| smiles = CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCSCCC(=O)N[C@@H](C(=O)N1)CC2=CNC3=CC=CC=C32)C(=O)N(C)[C@@H](CCCN)CO)CC(=O)N)[C@H](C)CC
| StdInChI = 1S/C40H63N9O8S/c1-6-23(3)34-38(55)46-31(20-32(42)51)36(53)45-29(40(57)49(5)26(22-50)11-10-16-41)14-17-58-18-15-33(52)44-30(19-25-21-43-28-13-9-8-12-27(25)28)37(54)47-35(24(4)7-2)39(56)48-34/h8-9,12-13,21,23-24,26,29-31,34-35,43,50H,6-7,10-11,14-20,22,41H2,1-5H3,(H2,42,51)(H,44,52)(H,45,53)(H,46,55)(H,47,54)(H,48,56)/t23-,24+,26+,29+,30-,31+,34+,35+/m1/s1
| StdInChIKey = UGNGRKKDUVKQDF-IHOMMZCZSA-N
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration =
}}

'''Barusiban''' ([[International Nonproprietary Name|INN]]) (code name '''FE-200440''') is a non-[[peptide]] [[drug]] which is among the most potent and selective [[oxytocin receptor]] [[receptor antagonist|antagonist]]s known.<ref name="LandgrafNeumann2008">{{cite book|author1=Rainer Landgraf|author2=Inga D. Neumann|title=Advances in Vasopressin and Oxytocin - From Genes to Behaviour to Disease|url=https://books.google.com/books?id=sDRBK1y7ObEC&pg=PA489|date=10 September 2008|publisher=Elsevier|isbn=978-0-08-093247-7|pages=194,489}}</ref><ref name="OffermannsRosenthal2008">{{cite book|author1=Stefan Offermanns|author2=Walter Rosenthal|title=Encyclopedia of Molecular Pharmacology|url=https://books.google.com/books?id=iwwo5gx8aX8C&pg=PA1278|date=14 August 2008|publisher=Springer Science & Business Media|isbn=978-3-540-38916-3|pages=1278–}}</ref> It was [[clinical trial|trialed]] by [[Ferring Pharmaceuticals]] as a treatment of [[preterm labor]] but failed to demonstrate effectiveness and was not pursued any further.<ref name="LandgrafNeumann2008" /><ref name="OuelletteJoyce2010">{{cite book|author1=Richard Ouellette|author2=Joseph Joyce|title=Pharmacology for Nurse Anesthesiology|url=https://books.google.com/books?id=7E1QfJSuppwC&pg=PA450|date=25 October 2010|publisher=Jones & Bartlett Publishers|isbn=978-0-7637-8607-6|pages=450–}}</ref>

==See also==
* [[Atosiban]]
* [[Epelsiban]]
* [[L-368,899]]
* [[L-371,257]]
* [[Retosiban]]

==References==
{{Reflist|2}}

{{Oxytocin and vasopressin receptor modulators}}

[[Category:Abandoned drugs]]
[[Category:Amines]]
[[Category:Carboxamides]]
[[Category:Indoles]]
[[Category:Oxytocin receptor antagonists]]
[[Category:Tocolytics]]